Kurv Yield Prem Strategy Tesla ETF (TSLP)
| Assets | $20.27M |
| Expense Ratio | 1.00% |
| PE Ratio | 120.49 |
| Shares Out | 1.14M |
| Dividend (ttm) | $5.70 |
| Dividend Yield | 32.17% |
| Ex-Dividend Date | Apr 8, 2026 |
| Payout Ratio | 3,849.64% |
| 1-Year Return | -9.73% |
| Volume | 12,293 |
| Open | 17.54 |
| Previous Close | 17.79 |
| Day's Range | 17.53 - 17.84 |
| 52-Week Low | 15.88 |
| 52-Week High | 26.52 |
| Beta | 1.43 |
| Holdings | 11 |
| Inception Date | Oct 27, 2023 |
About TSLP
Fund Home PageThe Kurv Yield Prem Strategy Tesla ETF (TSLP) is an exchange-traded fund that mostly invests in consumer discretionary equity. The fund seeks to provide current income and capped gains on the Tesla stock (TSLA) through a synthetic covered call strategy, collateralized by cash and short-term fixed-income instruments. The actively managed fund uses both standardized exchange-traded and FLEX options. TSLP was launched on Oct 27, 2023 and is issued by Kurv.
Top 10 Holdings
117.66% of assets| Name | Symbol | Weight |
|---|---|---|
| United States Treasury Bills 0% | WIB.0 06.11.26 | 41.08% |
| Tsla 06/18/2026 250 C | n/a | 26.41% |
| United States Treasury Bills 0% | B.0 09.03.26 | 25.52% |
| United States Treasury Bills 0% | B.0 12.24.26 | 22.82% |
| Tsla 06/18/2026 390 C | n/a | 14.89% |
| Tsla 06/18/2026 330 P | n/a | 1.12% |
| Fidelity Government Portfolio | FIGXX | 0.97% |
| OTHER ASSETS AND LIABILITIES | n/a | -0.05% |
| Tsla 05/01/2026 430 C | n/a | -0.37% |
| Tsla 06/18/2026 390 P | n/a | -14.73% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Apr 8, 2026 | $0.400 | Apr 9, 2026 |
| Mar 4, 2026 | $0.400 | Mar 5, 2026 |
| Feb 4, 2026 | $0.500 | Feb 5, 2026 |
| Jan 7, 2026 | $0.500 | Jan 8, 2026 |
| Dec 3, 2025 | $0.500 | Dec 4, 2025 |
| Nov 5, 2025 | $0.500 | Nov 6, 2025 |
News
Kurv Investment Management Completes Reorganization of Yield Premium Suite to Proprietary Trust
SAN FRANCISCO--(BUSINESS WIRE)--Kurv Investment Management, an ETF provider of tax-efficient, institutional-grade investment strategies, announces the successful reorganization of its Yield Premium Su...
AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca will showcase new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Soci...